Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients

Phase 2

Completed

• Conditions: Alzheimer Disease
• Interventions: Drug: Normal Saline 0.9%; Drug: GV1001 1.12 mg; Drug: GV1001 0.56 mg

• Registration Number: NCT03184467
• Lead Sponsor: GemVax & Kael

Brief Summary

This clinical study is designed as a multi-center, randomized, double-blind, placebo-controlled, parallel design, prospective, phase II clinical trial.

An eligible subject who meets inclusion and exclusion criteria is randomly assigned to three groups: study group 1 (GV1001 0.56 mg), study group 2 (GV1001 1.12 mg) or placebo group. A randomized subject is administered either GV1001 or placebo in a total of 14 times and will be evaluated for the efficacy and safety at week of 24.

Detailed Description

GV1001 0.56 mg, 1.12 mg or placebo is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

1. Control group (placebo): 30 subjects

2. Study group 1 (GV1001 0.56 mg): 30 subjects

3. Study group 2 (GV1001 1.12 mg): 30 subjects.

Study Timeline

• Study First Submitted: 2017-06-09
• Study First Submitted QC: 2017-06-09
• Study First Posted: 2017-06-12
• Study Start: 2017-09-05
• Primary Completion: 2019-09-05
• Study Completion: 2019-09-19
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-08
• Last Update Posted: 2020-07-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

1. 55 to 85 years of age
2. A patient who satisfies diagnostic criteria for dementia in DSM-IV
3. Probable Alzheimer's disease in NINCDS-ADRDA
4. K-MMSE ≤ 19 at screening and randomization visit
5. GDS 5~6 stage
6. MRI or CT scan within 12 months prior to screening visit that proves Alzheimer's disease without any other disease that may cause dementia
7. A patient taking stable doses of donepezil for more than 3 months before screening visit
8. A patient who are able to visit a hospital (including inpatient and outpatient based) and receive cognitive and other tests
9. A patient with a caregiver who can accompany all visits and supervise the subject's compliance with the procedures and study drug prescribed in the protocol, and provide detailed information about the patient
10. Written informed consent by a patient or legal representative

Exclusion Criteria

1. Any other cause of dementia shown by CT / MRI findings and neurological examination within 12 months of screening visit

   • Possible, probable or definite vascular dementia according to the NINDS-AIREN
   • Other central nervous system diseases that may cause cognitive impairment (cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease, etc.)
   • Neurological deficits such as delusions, delirium, epilepsy

2. Vitamin B12, folic acid, syphilis serology, and thyroid stimulating hormone (TSH) results are thought to contribute to the severity of dementia or cause dementia

3. A patient who are considered ineligible for this study by investigator due to concurrent or history of significant psychiatric conditions (eg. schizophrenia or bipolar affective disorder)

4. A patient with a history of known or suspected seizures including febrile seizures, a history of significant head trauma with loss of consciousness or recent unconsciousness that is not explained

5. A patient with acute or unstable cardiovascular disease, active peptic ulcer, uncontrolled hypertension, uncontrolled diabetes or insulin dependent patients or any medical condition that may interfere with the completion of clinical trials

6. Hypersensitivity to investigational medicinal products

7. History of alcohol, substance abuse or dependence (except nicotine dependence) within the last 2 years

8. Concurrent malignancies or invasive cancers diagnosed within the past 5 years except for non-metastatic basal cell carcinoma or squamous cell carcinoma of skin, in situ carcinoma of the uterine cervix or non-metastatic prostate cancer

9. Renal impairment (creatinine clearance (CLcr) <30 mL / min)

10. Severe liver dysfunction (ALT or AST> 2 times the upper limit of normal)

11. A patient taking other drugs other than donepezil to treat Alzheimer's disease or other cognitive impairment

12. A patient taking other drugs other than anticholinergic drugs, cholinergic drugs (local usages are allowable, such as pilocarpine eye drops), antidepressants (tricyclic antidepressant, MAO inhibitor) antipsychotics, donepezil to treat Alzheimer's disease

13. Women at childbearing age who do not consent using medicinally acceptable contraception (such as surgical sterilization, intrauterine contraceptive device, condom or diaphragm, an injectable or inserted contraceptive) during the study

14. Pregnancy or breast feeding

15. A patient who participated in other clinical trials within 4 weeks prior to this study

16. 35 kg weight or below

17. A patient who had experienced this study drug

18. A patient who had participated in a clinical trial for Alzheimer dementia vaccine within last 6 months

19. Any other patients who are considered to be ineligible for this study by an investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control group	Normal Saline 0.9%	Normal saline 0.9%
Study group 2	GV1001 1.12 mg	GV1001 1.12 mg
Study group 1	GV1001 0.56 mg	GV1001 0.56 mg

Primary Outcome Measures

Name	Time	Method
SIB (Severe Impairment Battery)	week 24	Change in SIB compared to the baseline and week 24

Secondary Outcome Measures

Name	Time	Method
K-MMSE (Korean-Mini-Mental State Examination)	week 24	Change in K-MMSE compared to the baseline and week 24
CDR-SOB (Clinical Dementia Rating-Sum of Box)	week 24	Change in CDR-SOB compared to the baseline and week 24
ADCS-ADL-severe (Alzheimer's Disease Cooperative Study-Activities of Daily Living scale-severe)	week 24	Change in ADCS-ADL-severe compared to the baseline and week 24
NPI (Neuropsychiatric Inventory)	week 24	Change in NPI compared to the baseline and week 24
GDS (Global Deterioration Scale)	week 24	Change in GDS compared to the baseline and week 24
CIBIC-plus (Clinician Interview-Based Impression of Change-Plus)	week 24	Change in CIBIC-plus compared to the baseline and week 24

Trial Locations

Locations (1)

Hanyang University Guri Hospital; 🇰🇷 Guri-si, Gyunggi-do, Korea, Republic of